US EditionCERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital
Summary by defenseworld.net
1 Articles
1 Articles
All
Left
Center
1
Right
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital
D. Boral Capital restated their hold rating on shares of CERo Therapeutics (NASDAQ:CERO – Free Report) in a research report sent to investors on Friday,Benzinga reports. Several other brokerages have also issued reports on CERO. D Boral Capital raised CERo Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 22nd. Maxim Group initiated coverage on CERo Therapeutics in a research note on Monday, May 19th. They set a “buy” ra…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
